1. Introduction {#sec1-marinedrugs-17-00422}
===============

Dibenzofurans have been isolated from plants, mushrooms, and marine organisms. Although lichens were their first reported natural source, isolation of dibenzofurans from filamentous fungi has been increasingly reported \[[@B1-marinedrugs-17-00422]\]. Usnic acid (UA) is the most representative dibenzofuran natural product and has interesting chemical and pharmacological properties with a broad spectrum of biological activities such as antibacterial, antiviral, anti-inflammatory, antiprotozoal, antifungal, anti-proliferative, phytotoxic, UV filter, and anti-osteoclastogenic activities \[[@B2-marinedrugs-17-00422],[@B3-marinedrugs-17-00422],[@B4-marinedrugs-17-00422],[@B5-marinedrugs-17-00422],[@B6-marinedrugs-17-00422]\]. UA is generally distributed in lichen genera such as *Usnea* (Usneaceae), *Cladonia* (Cladoniaceae), *Hypotrachyna* (Parmeliaceae), *Lecanora* (Lecanoraceae), *Ramalina* (Ramalinaceae), *Evernia*, *Parmelia* (Parmeliaceae), and *Alectoria* (Alectoriaceae) \[[@B7-marinedrugs-17-00422]\]. There are also a few reports on the isolation of UA or its derivatives from non-lichen sources \[[@B4-marinedrugs-17-00422]\].

*Mycosphaerella* is the largest genus of Ascomycota, with more than 10,000 species. *Mycosphaerella* species produce secondary metabolites including rosigenin \[[@B8-marinedrugs-17-00422]\], rubellins A and B \[[@B9-marinedrugs-17-00422]\], (−)-mycousnine, and (+)-isomycousnine \[[@B10-marinedrugs-17-00422]\]. Mycousfuranine and mycousnicdiol have also been recently reported to possess antifungal activity \[[@B11-marinedrugs-17-00422]\]. *Mycosphaerella* species are generally known as foliicolous plant pathogens, isolated from the leaves of plants; however, some species are also found in marine environments. *M. ascopliylli* and *M. pelvetiae* are endophytes of the brown algae *Ascophyllum nodusum* and *Pelvetia canaliculate*, respectively, while *M. apophlaeae* is the symbiont of the rhodophyte, *Apophlaea lyallii* \[[@B12-marinedrugs-17-00422],[@B13-marinedrugs-17-00422],[@B14-marinedrugs-17-00422]\]. In addition, there are recent taxonomy studies demonstrating that *Mycosphaerella* is not just a terrestrial genus but is spread across marine environments as well. For example, *Mycosphaerella* sp. was one of the two dominant fungal communities in samples collected from salt marshes in California Bay and the Atlantic east coast of USA \[[@B15-marinedrugs-17-00422],[@B16-marinedrugs-17-00422]\].

During the course of the chemical analysis of cultured fungal strains, isolated from marine sediments, we isolated two new usnic acid congeners, mycousfurans A and B (**1** and **2**), along with the previously reported compounds, (−)-mycousnine (**3**), (−)-placodiolic acid (**4**), and (+)-usnic acid (**5**), from extracts of *Mycosphaerella* sp. ([Figure 1](#marinedrugs-17-00422-f001){ref-type="fig"}). Herein, we describe the isolation, structural elucidation, and bioactivities of mycousfurans A and B (**1** and **2**).

2. Results {#sec2-marinedrugs-17-00422}
==========

2.1. Isolation and Structure Elucidation {#sec2dot1-marinedrugs-17-00422}
----------------------------------------

Compound **1** was obtained as an amorphous yellowish powder, and its molecular formula was determined to be C~18~H~20~O~7~ based on a (+)-high-resolution electrospray ionization mass spectrometry (HRESIMS) *m/z* 349.1302 \[M + H\]^+^, indicating 9 degrees of unsaturation. The IR spectrum of **1** indicated the presence of hydroxyl (3387, 3232 cm^−1^) and ketone functionalities (1616 cm^−1^), and the UV spectrum showed similar absorption patterns to those of dibenzofuran derivatives. The ^1^H NMR spectrum of **1** showed five methyl singlets (δ~H~ 1.62, 2.04, 2.61, 3.49, 3.81), two doublets at δ~H~ 2.96, *J* = 17.5 Hz (1H) and δ~H~ 3.15, *J* = 17.5 Hz (1H), a singlet of an olefinic proton (δ~H~ 5.55, s), and two singlets of phenolic hydroxyl protons (δ~H~ 9.34, 13.34). The ^13^C NMR, in combination with the heteronuclear single quantum correlation (HSQC) spectrum, showed two ketone carbonyls (δ~C~ 200.5, 201.2), six non-protonated aromatic carbons (δ~C~ 102.0, 106.5, 107.5, 157.1, 159.6, 163.3), five methyl carbons (δ~C~ 7.4, 16.6, 31.3, 50.9, 56.9), two bridgehead quaternary carbons (δ~C~ 57.9, 111.6), a methine sp^2^ carbon (δ~C~ 100.6), and one methylene sp^3^ carbon (δ~C~ 34.3) ([Table 1](#marinedrugs-17-00422-t001){ref-type="table"}). The heteronuclear multiple bond correlation (HMBC) correlations from the phenolic proton 7-OH (δ~H~ 9.34) to C-6 (δ~C~ 102.0), C-7 (δ~C~ 163.3), and C-8 (δ~C~ 107.5); from the phenolic proton 9-OH (δ~H~ 13.34) to C-8 (δ~C~ 107.5) and C-9a (δ~C~ 106.5); from the methyl protons H~3~-13 (δ~H~ 2.61, s) to C-6 (δ~C~ 102.0) and C-12 (δ~C~ 201.2); and from H~3~-11 (δ~H~ 2.04, s) to C-8 (δ~C~ 107.5), established the substitution pattern of the A ring. The HMBC correlations from H~2~-4 (δ~H~ 2.96, d, *J* = 17.5 and 3.15, d, *J* = 17.5) to C-2 (δ~C~ 106.6) and C-4a (δ~C~ 34.3); from H~3~-15 (δ~H~ 3.81, s) to C-2 (δ~C~ 106.6) and C-3 (δ~C~ 175.4), and from the angular methyl protons H~3~-10 (δ~H~ 1.62, s) to C-1 (δ~C~ 200.5), C-4a (δ~C~ 34.3), and C-9b (δ~C~ 57.9) established the substitution pattern of ring C. Finally, the linkage between C-9a and C-9b was corroborated by the observation of the cross peak from H~3~-10 to C-9a in the HMBC spectrum. Combining the 1D and 2D NMR data and the molecular formula, the presence of an ether linkage between C-4a (δ~C~ 111.6) and C-5a (δ~C~ 157.1) was proposed. Moreover, the HMBC correlation from the methoxyl protons H~3~-14 (δ~H~ 3.49, s) to C-4a permitted the placement of the methoxy group at C-4a, thus completing the structural assignment of **1**, as shown in [Figure 2](#marinedrugs-17-00422-f002){ref-type="fig"}. The NOESY correlations from H~3~-14/H~3~-10 and H~2~-4/H~3~-10 indicated that the B/C ring junction was *cis*-orientated ([Figure S5](#app1-marinedrugs-17-00422){ref-type="app"}) \[[@B10-marinedrugs-17-00422]\].

Compound **2** was obtained as a yellow amorphous powder. Its molecular formula was determined to be C~18~H~20~O~7~ based on a (+)-HRESIMS *m/z* 349.1305 \[M + H\]^+^ and ^13^C NMR data. Interpretation of the NMR data revealed that the structure of **2** was almost identical to that of **1**, except that **2** possessed a methyl group at C-6 and an acetyl group at C-8 ([Figure 1](#marinedrugs-17-00422-f001){ref-type="fig"}). The HMBC correlations from H~3~-10 (δ~H~ 1.66, s) to C-9a (δ~C~ 106.1), 9-OH (δ~H~ 9.61, s) to C-8 (δ~C~ 107.1) and C-9a (δ~C~ 106.1), H~3~-13 (δ~H~ 2.73, s) to C-8, and H~3~-11 (δ~H~ 2.02, s) to C-5a (δ~C~ 160.7) supported the positions of the acetyl group at C-8, and consequently placed a methyl group at C-6 (δ~C~ 100.4) ([Figures S9 and S10](#app1-marinedrugs-17-00422){ref-type="app"}). Thus, **2** was defined as a regioisomer of **1**.

The absolute configurations of the stereogenic carbons of **1** were established via the comparison of the experimental electronic circular dichroism (ECD) spectrum with that generated by the computer-assisted ECD calculation. The ECD spectrum of **1** fits well with that of the calculated ECD spectrum of 4a*S* and 9b*R* stereoisomers ([Figure 3](#marinedrugs-17-00422-f003){ref-type="fig"}). Both experimental and calculated ECD spectra of **1** showed the negative absorption in the range from 210 to 235 nm and the positive absorption from 250 to 310 nm ([Figure 3](#marinedrugs-17-00422-f003){ref-type="fig"}). Therefore, the absolute configurations of C-4a and C-9a in **1** was established as 4a*S* and 9b*R*. The experimental ECD spectrum of **2** was almost identical to that of **1**, leading to the conclusion that the absolute configurations of C-4a and C-9a in **2** were 4a*S* and 9b*R*.

Three known UA derivatives were also isolated together with **1** and **2** and they were identified as (−)-mycousnine (**3**) \[[@B10-marinedrugs-17-00422]\], (−)-placodiolic acid (**4**) \[[@B17-marinedrugs-17-00422]\], and (+)-usnic acid (**5**) \[[@B18-marinedrugs-17-00422]\] via comparison of their NMR and MS data with those reported in the literatures.

2.2. Bioactivity {#sec2dot2-marinedrugs-17-00422}
----------------

Compounds **1**--**5** were tested for their antibacterial activity using three Gram-positive bacteria (*Bacillus substilis* ATCC 6633, *Kocuria rhizophila* ATCC 9341, *Staphylococcus aureus* ATCC 6538) and three Gram-negative bacteria (*Escherichia coli* ATCC 11775, *Salmonella typhimurium* ATCC 14208, *Klebsiella pneumonia* ATCC 4352). Compound **1** exhibited the minimal inhibitory concentration (MIC) values of 8 μg/mL and 32 μg/mL, while **2** exhibited MIC values of 16 μg/mL and 32 μg/mL, against *K. rhizophila* and *S. aureus,* respectively ([Table 2](#marinedrugs-17-00422-t002){ref-type="table"}). Compounds **1** and **2** showed no antibacterial activity against *B. substilis* and Gram-negative bacteria. Since the MIC values of **3**--**5** indicated stronger antibacterial activity than that of **1** and **2** against Gram-positive bacteria, it was suggested that the substituents in ring C could play a role in the antibacterial activity.

3. Materials and Methods {#sec3-marinedrugs-17-00422}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00422}
------------------------------------

Optical rotations were measured using an Autopol III (Rudolph Research Analytical, Hackettstown, NJ, USA) polarimeter with a 5-cm cell. ECD spectra were recorded using a Chirascan™-plus CD Spectrometer (Applied Photophysics Ltd., Surrey, UK) and the UV spectra were recorded on a Scinco UVS-2100 spectrophotometer (Sinco, Daejeon, Korea). IR spectra were obtained using a Scimitar 800 FT-IR spectrometer (Varian Inc., Palo Alto, CA, USA). NMR spectra were recorded on a Bruker Avance 700 MHz spectrometer (Bruker Biospin Group, Karlsruhe, Germany); The residual solvent signals of CDCl~3~ (δ~H~ 7.26, δ~C~ 77.0) were referenced for the ^1^H and ^13^C chemical shift values. HRESIMS spectra were obtained using a JEOL JMS-AX505WA mass spectrometer (JEOL Ltd., Tokyo, Japan). Low-resolution LC-MS data were obtained using an Agilent Technologies 6120 quadrupole LC/MS system (Agilent Technologies, Santa Clara, CA, USA) with a reversed-phase C18 column (Phenomenex Luna C18 (2), 50 mm × 4.6 mm, 5 μm) at a flow rate of 1.0 mL/min. Column chromatography separation was performed using a C18 column (40--63 m, ZEO prep 90), eluting with a gradient of methanol and water. The fractions were purified using a WATERS^TM^ (Milford, MA, USA) 1525 binary HPLC (high-performance liquid chromatography) pump, equipped with a WATERS 2489 UV visible detector using a WATERS reversed-phase HPLC Watchers 120 ODS-BP (250 mm × 10 mm, 5 μm) column, eluting with 80% CH~3~CN in H~2~O at flow rate of 2.5 mL/min.

3.2. Fungal Material {#sec3dot2-marinedrugs-17-00422}
--------------------

The strain F8015-2B was isolated from a marine sediment at a 5-m depth in Donghae-si, Gangwon-do, South Korea. The collected sediment was dried on a clean bench for 24 h and then crushed using a sterile spoon. The powder was stamped onto 1/3 marine agar medium and incubated at 27 °C. After two weeks, fungal spores were observed. The spores were cultured via repeated inoculation on potato dextrose agarplates. F8015-2B was identified as *Mycosphaerella* sp. based on a 99.6% (496/498) similarity of 18S rRNA genes to the *Mycosphaerella nawae* strain MY3.

3.3. Fermentation, Extraction, and Purifircation {#sec3dot3-marinedrugs-17-00422}
------------------------------------------------

The strain F8015-2B was cultured in 6 × 2.5-L Ultra Yield Flasks (Thomson Instrument Company, Oceanside, CA, USA), each containing 1 L of potato dextrose broth (PDB) dissolved in seawater. The fungus was cultivated on seed agar blocks in 6 × 2.5-L Ultra Yield Flasks, each containing 1 L of PDB dissolved in seawater at 27 °C and 140 rpm in a shaking incubator. After seven days, the mycelia were filtered from the broth using gauze filtration and extracted with acetone and methanol. The broth was extracted with EtOAc and evaporated to obtain the crude extract (4.01 g).

The crude extract was fractionated into eight fractions with a silica gel open column chromatography using a step-gradient with a mixture of CH~2~Cl~2~ and MeOH as an eluent. Fractions 1 (974.9 mg), 2 (280.1 mg), and 3 (420.1 mg) were subjected to a reversed-phase HPLC (Phenomenex luna C18 column, 250 mm × 10 mm, 5 μm, flow rate = 2.0 mL/min) and eluted with 65% CH~3~CN in distilled water to yield **1** (7.5 mg), **2** (3.3 mg), **3** (56.3 mg), **4** (28.7 mg), and **5** (6.8 mg).

*Mycousfuran A* (**1**): amorphous powder, \[α\]~D~^25^ + 11 (*c* 1.00, CHCl~3~); UV (MeOH) *λ~max~* (log ε) 200 (2.15), 281 (2.09), and 349 (1.24) nm; IR (KBr) ν~max~ 3387, 3232, and 1616 cm^−1^; CD λ~ext~ (MeOH) nm (Δε): 282 (+0.11), 246 (+0.03) \[236(0)\]; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-17-00422-t001){ref-type="table"}; (+)-HRESIMS, *m/z* 349.1302 \[M + H\]^+^ (calcd for C~18~H~20~O~7~, 349.1287).

*Mycousfuran B* (**2**): amorphous yellowish powder, \[α\]~D~^25^ + 15 (*c* 1.00, CHCl~3~); UV (MeOH) *λ~max~* (log ε) 200 (2.15), 281 (2.09), and 349 (1.24) nm; IR (KBr) ν~max~ 3325, 3198, and 1625 cm^−1^; CD λ~ext~ (MeOH) nm (Δε): 282 (+0.12), 246 (+0.06) \[236(0)\]; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-17-00422-t001){ref-type="table"}; (+)-HRESIMS, *m/z* 349.1305 \[M + H\]^+^ (calcd for C~18~H~20~O~7~, 349.1287).

3.4. Computer-Assisted Conformational Analyses and ECD Calculations {#sec3dot4-marinedrugs-17-00422}
-------------------------------------------------------------------

Preliminary conformational analyses of **1** and **2** were performed with Merck Molecular Force Field (MMFF) by Spartan 10 (Wavefunction, Irvine, CA, USA). The two lowest energy conformers of **1** and **2** were geometrically optimized with the B3LYP/6-31G(d,p) level of density functional theory (DFT) in methanol using Gaussian 16 (Expanding the limits of computational chemistry, Wallingford, CT, USA). The computer-assisted ECD calculation was carried out with the B3LYP/6-31G(d,p) level of time-dependent density functional theory (TDDFT). The calculated ECD spectra of **1** and **2** were obtained via visualization of SpecDis version 1.71 (SpecDis, Berlin, Germany) in combination with the calculated ECD spectra of each conformer on the basis of Boltzmann distribution theory and their relative Gibbs free energy.

3.5. Antibacterial Activity {#sec3dot5-marinedrugs-17-00422}
---------------------------

Three Gram-positive (*Bacillus substilis* ATCC 6633, *Kocuria rhizophila* ATCC 9341, *Staphylococcus aureus* ATCC 6538) and three Gram-negative (*Escherichia coli* ATCC 11775, *Salmonella typhimurium* ATCC 14208, *Klebsiella pneumonia* ATCC 4352) strains were used. These bacteria were inoculated onto a Mueller--Hinton agar medium and allowed to grow for 24 h at 37 °C. The bacterial colonies were cultivated in 15-mL round-bottom tubes containing 5 mL of Mueller--Hinton broth (MHB) at 37 °C and 220 rpm for 24 h. One hundred microliter aliquots of test compounds and positive controls (vancomycin and ampicillin) at a concentration of 256 µg/mL in DMSO were added to different wells of a 96-well microtiter plate containing 50 µL of MHB. The samples were serially diluted and 50 µL of bacterial MHB medium was adjusted to a concentration of 1/100 dilution. McFarland 0.5% standard was added to the wells. The 96-well microtiter plate was incubated for 24 h at 37 °C. Subsequently, the minimum inhibitory concentration was determined as the concentration of compounds inhibiting bacterial growth \[[@B19-marinedrugs-17-00422]\].

4. Conclusions {#sec4-marinedrugs-17-00422}
==============

In conclusion, mycousfurans A and B (**1** and **2**) and other usnic acid congeners, were isolated from a marine sediment-derived fungus *Mycosphaerella* sp. The structures of **1** and **2** were established using 1D and 2D NMR spectra. The absolute configurations of the stereogenic carbons of **1** and **2** were determined using NOESY experiments and a comparison between the experimental and calculated ECD spectra. Compounds **1** and **2** exhibited antibacterial activity against *K. rhizophila*, *S. aureus*, and *E. coli*. The present study is the first report of the antibacterial compounds, produced by *Mycosphaerella* sp., which was isolated from the marine environment.

The following are available online at <https://www.mdpi.com/1660-3397/17/7/422/s1>, Figure S1: ^1^H NMR spectrum (700 MHz, CDCl~3~) of **1**, Figure S2: ^13^C NMR spectrum (175 MHz, CDCl~3~) of **1**, Figure S3: HSQC spectrum (700 MHz, CDCl~3~) of **1**, Figure S4: HMBC spectrum (700 MHz, CDCl~3~) of **1**, Figure S5: NOESY spectrum (700 MHz, CDCl~3~) of **1**, Figure S6: ^1^H NMR spectrum (700 MHz, CDCl~3~) of **2**, Figure S7: ^13^C NMR spectrum (175 MHz, CDCl~3~) of **2**, Figure S8: HSQC spectrum (700 MHz, CDCl~3~) of **2**, Figure S9: HMBC spectrum (700 MHz, CDCl~3~) of **2**, Figure S10: Expanded HMBC of **2**.

###### 

Click here for additional data file.

J.L. (Jihye Lee) isolated the compounds, elucidated the chemical structure, and performed bioassays. J.L. (Jusung Lee) performed the large-scale culture of fungal strains and elucidated the chemical structure. G.J.K., J.-W.N., and H.C calculated the ECD spectra and wrote the manuscript. W.W. performed sampling and isolated a fungal strain from a sediment. I.Y. contributed NMR analysis and wrote the manuscript. S.-J.N. was the project leader guiding the chemical analysis experiments. H.K. headed the project and chemical analysis, provided the microbial strains, and wrote the manuscript.

This research was funded by Basic Science Research Program through the National Research Foundation of Korea (NRF) of the Ministry of Science, ICT & Future Planning, grant number NRF-2017R1D1A1B03028172 (to S.-J.N.) and NRF-2019R1A2C2005492 (to H.K.).

The authors declare no conflict of interest.

![Chemical structures of mycousfurans A and B (**1** and **2**), (−)-mycousnine (**3**), (−)-placodiolic acid (**4**), and (+)-usnic acid (**5**), isolated from *Mycosphaerella* sp.](marinedrugs-17-00422-g001){#marinedrugs-17-00422-f001}

![Key HMBC (**a**) and NOESY (**b**) correlations of mycousfuran A (**1**).](marinedrugs-17-00422-g002){#marinedrugs-17-00422-f002}

![Experimental and calculated ECD spectra of **1** and **2**.](marinedrugs-17-00422-g003){#marinedrugs-17-00422-f003}

marinedrugs-17-00422-t001_Table 1

###### 

^1^H and ^13^C NMR spectroscopic data (700 MHz and 175 MHz in CDCl~3~) for mycousfurans (**1**--**2**).

  -------------------------------------------------------------------------------------------
  Position   1             HMBC               2                             
  ---------- ------------- ------------------ --------------- ------------- -----------------
  1          200.5, C                                         201.0, C      

  2          100.6, CH     5.55, s                            100.2, CH     5.55, s

  3          175.4, C                                         175.9, C      

  4α\        34.3, CH~2~   3.15, d (17.5),\   2, 4a\          34.2, CH~2~   3.20, d (17.5)\
  4β                       2.96, d (17.5)     2, 4a                         2.94, d (17.5)

  4a         111.6, C                                         110.6, C      

  5a         157.1, C                                         160.7, C      

  6          102.0, C                                         100.4, C      

  7          163.3, C                                         165.5, C      

  8          107.5, C                                         107.1, C      

  9          159.6, C                                         156.4, C      

  9a         106.5, C                                         106.1, C      

  9b         57.9, C                                          58.9, C       

  10         16.6, CH~3~   1.62, s            1, 4a, 9a, 9b   16.2, CH~3~   1.66, s

  11         7.4, CH~3~    2.04, s            8               7.5, CH~3~    2.02, s

  12         201.2, C                                         203.8, C      

  13         31.3, CH~3~   2.61, s            6, 12           32.9, CH~3~   2.73, s

  14         50.9, CH~3~   3.49, s            4a              50.3, CH~3~   3.47, s

  15         56.9, CH~3~   3.81, s            2, 3            56.8, CH~3~   3.84, s

  7-OH                     13.34, s           6, 7, 8                       14.32, s

  9-OH                     9.34, s            8, 9a                         9.61, s
  -------------------------------------------------------------------------------------------

marinedrugs-17-00422-t002_Table 2

###### 

The MIC values (g/mL)^1^ of **1**--**5** against Gram-positive and Gram-negative bacteria.

  Compound     Gram (+) Bacteria   Gram (−) Bacteria                         
  ------------ ------------------- ------------------- ----- ------- ------- -------
  **1**        \>128               8                   32    \>128   \>128   \>128
  **2**        \>128               16                  32    \>128   \>128   \>128
  **3**        4                   8                   4     \>128   \>128   \>128
  **4**        4                   8                   4     \>128   \>128   \>128
  **5**        2                   8                   16    \>128   \>128   \>128
  Vancomycin   0.25                0.25                0.5   \>128   \>128   \>128
  Ampicillin   0.5                 0.25                2     16      8       \>128

^1^ Each sample was tested in triplicate and repeated three times.

[^1]: These authors contributed equally to this work.
